William Blum

13.1k total citations
188 papers, 5.6k citations indexed

About

William Blum is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, William Blum has authored 188 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Hematology, 77 papers in Molecular Biology and 46 papers in Oncology. Recurrent topics in William Blum's work include Acute Myeloid Leukemia Research (101 papers), Hematopoietic Stem Cell Transplantation (33 papers) and Acute Lymphoblastic Leukemia research (31 papers). William Blum is often cited by papers focused on Acute Myeloid Leukemia Research (101 papers), Hematopoietic Stem Cell Transplantation (33 papers) and Acute Lymphoblastic Leukemia research (31 papers). William Blum collaborates with scholars based in United States, Canada and Germany. William Blum's co-authors include Guido Marcucci, John C. Byrd, Rebecca B. Klisovic, Amy J. Johnson, Steven M. Devine, Kenneth K. Chan, Ramiro Garzon, Alice S. Mims, Alan G. Ramsay and John G. Gribben and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Journal of Clinical Investigation.

In The Last Decade

William Blum

181 papers receiving 5.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William Blum United States	43	2.7k	2.5k	1.3k	1.1k	1.0k	188	5.6k
Maria Teresa Voso Italy	39	2.7k 1.0×	2.4k 1.0×	1.1k 0.8×	1.0k 0.9×	963 0.9×	239	5.3k
Adriano Venditti Italy	40	3.6k 1.3×	2.1k 0.8×	1.0k 0.8×	1.4k 1.2×	695 0.7×	259	5.6k
Ulrich Jäger Austria	45	2.4k 0.9×	1.8k 0.7×	1.7k 1.2×	1.2k 1.1×	1.2k 1.1×	172	5.7k
P. Maslak United States	32	1.7k 0.6×	2.8k 1.1×	3.1k 2.3×	683 0.6×	1.1k 1.1×	116	6.3k
Clayton A. Smith United States	35	2.9k 1.1×	2.7k 1.1×	1.1k 0.9×	1.1k 1.0×	748 0.7×	129	5.5k
Jeffrey Tyner United States	46	2.9k 1.1×	3.3k 1.3×	1.3k 1.0×	2.1k 1.9×	1.3k 1.3×	238	7.1k
Stéphane de Botton France	44	4.1k 1.5×	3.0k 1.2×	1.2k 0.9×	1.3k 1.2×	677 0.7×	201	6.2k
Bruno C. Medeiros United States	33	3.4k 1.2×	2.5k 1.0×	1.1k 0.8×	864 0.8×	634 0.6×	170	5.3k
David A. Rizzieri United States	44	4.3k 1.6×	3.0k 1.2×	2.5k 1.9×	1.6k 1.4×	1.6k 1.5×	309	8.1k
Lothar Bergmann Germany	39	1.4k 0.5×	2.1k 0.8×	1.4k 1.0×	662 0.6×	1.0k 1.0×	182	4.8k

Countries citing papers authored by William Blum

Since Specialization

Citations

This map shows the geographic impact of William Blum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Blum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Blum more than expected).

Fields of papers citing papers by William Blum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Blum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Blum. The network helps show where William Blum may publish in the future.

Co-authorship network of co-authors of William Blum

This figure shows the co-authorship network connecting the top 25 collaborators of William Blum. A scholar is included among the top collaborators of William Blum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Blum. William Blum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nicolet, Deedra, Daelynn R. Buelow, Shelley Orwick, et al.. (2025). Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies. Leukemia. 39(3). 623–631. 1 indexed citations

Cortes, Jörge E., Gail J. Roboz, Maria R. Baer, et al.. (2025). Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. Journal of Hematology & Oncology. 18(1). 7–7. 7 indexed citations

Pollyea, Daniel A., Tessa Kerre, Dries Deeren, et al.. (2025). Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia. Leukemia. 39(12). 2907–2915. 1 indexed citations

Abdul‐Hay, Maher, Onyee Chan, Namrata S. Chandhok, et al.. (2025). Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS). Blood. 146(Supplement 1). 768–768.

Blum, William, et al.. (2024). Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis. Blood. 144(Supplement 1). 3521–3521. 1 indexed citations

Wang, Eunice S., Jörge E. Cortes, Justin M. Watts, et al.. (2024). Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib. Blood. 144(Supplement 1). 1514–1514.

Kohlschmidt, Jessica, Krzysztof Mrózek, Deedra Nicolet, et al.. (2023). Association of social deprivation with survival in younger adult patients with AML: an Alliance study. Blood Advances. 7(15). 4019–4023. 5 indexed citations

Mrózek, Krzysztof, Jessica Kohlschmidt, James S. Blachly, et al.. (2023). Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 37(4). 788–798. 31 indexed citations

Nicolet, Deedra, Krzysztof Mrózek, Christopher J. Walker, et al.. (2023). Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients. Blood. 142(Supplement 1). 2954–2954.

10.

Walker, Alison R., John C. Byrd, James S. Blachly, et al.. (2020). Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression. Clinical Cancer Research. 26(22). 5852–5859. 27 indexed citations

11.

Blum, William. (2019). Evaluating lambda terms with traversals. Theoretical Computer Science. 802. 77–104. 1 indexed citations

12.

Cortes, Jörge E., Daniel J. DeAngelo, Harry P. Erba, et al.. (2018). Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 132(Supplement 1). 26–26. 26 indexed citations

13.

Drenberg, Christina D., Alice A. Gibson, Stanley Pounds, et al.. (2017). OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Research. 77(8). 2102–2111. 46 indexed citations

14.

Park, Il‐Kyoo, Daelynn R. Buelow, Clifford J. Whatcott, et al.. (2017). TP-0903, a Novel Axl Inhibitor with Activity in Drug Resistant FLT3-ITD+ AML through a Mechanism That Includes FLT3 Inhibition. Blood. 130. 2522–2522. 1 indexed citations

15.

Cortes, Jörge E., Elie Traer, Eunice S. Wang, et al.. (2017). IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 130. 1312–1312. 7 indexed citations

16.

Ranganathan, Parvathi, Trinayan Kashyap, Xueyan Yu, et al.. (2016). XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus. Clinical Cancer Research. 22(24). 6142–6152. 67 indexed citations

17.

DeAngelo, Daniel J., Kristen E. Stevenson, Donna Neuberg, et al.. (2015). A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. Blood. 126(23). 80–80. 37 indexed citations

18.

Huang, Xiaomeng, Sebastian Schwind, Bo Yu, et al.. (2013). Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia. Clinical Cancer Research. 19(9). 2355–2367. 151 indexed citations

19.

Blum, William, Rebecca B. Klisovic, Heiko Becker, et al.. (2010). Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias. Journal of Clinical Oncology. 28(33). 4919–4925. 71 indexed citations

20.

Andritsos, Leslie A., Amy J. Johnson, Gerard Lozanski, et al.. (2008). Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 26(15). 2519–2525. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact